ANOTHER FDA RULING ON CV-19 TEST KITS WHILE FAUCI INVENTS FAKE ILLNESSES- WE HAVE NO IDEA HOW MANY ARE INFECTED!
by Dave Hodges
TheCommonSenseShow.com
Sunday, May 17, 2020
ANOTHER FDA RULING ON WHITE HOUSE CV-19 TEST KITS- WE HAVE NO IDEA HOW MANY ARE INFECTED
America has just had the biggest fraud perpetrated upon the American people in world history, not American Whether one is validating a treatment efficacy or providing a more “reliable” claim for diagnosis, one needs to establish the false positive rate in order to determine whether or not effective treatment or accurate diagnostics falls within acceptable limits. And of course, consistency is needed in the testing process and that is established through multiple studies in which consistent results are obtained. In health testing, a margin of error of less than 5% is acceptable. Anything greater than this calls into question the validity of the diagnostics.
On April 18, 2020, the FDA High Commissioner issued the following information:
Fraud #1-The FDA Invalidates the Test Kits
At question in this report is the efficacy of the diagnostic procedures being utlized by federal and state health officials in determining the true infection rate in the United States which can be used as a guide to impose restrictions upon the people of this nation. Sometimes in investigative reporting, we can use the words of the investigated to convict them of wrongdoing. This is certainly the case here.
From the FDA in an April Statement from the Commissioner of Food and Drugs -Food and Drug Administration Stephen M. Hahn MD., in which the FDA admits that they have no intention of validating the testing numbers for COVID-19. Instead, the FDA admits that they will let the test developers validate their own testing reliability and validity.
…Recognizing that more flexibility was needed during a pandemic of this scale and speed, and incorporating feedback from the medical community, states and test developers, we have also provided regulatory flexibility for serological tests in an effort to provide laboratories and health care providers with early access to these tests with the understanding that the FDA had not reviewed or authorized (or “approved”) them, at least not initially, and these tests should not be used for diagnosing or excluding active SARS-CoV-2 infection.
The Rest…HERE
